Corcept Non Current Assets Total vs Total Current Assets Analysis

CORT Stock

USD 23.32 0.05 0.21%

Corcept Therapeutics financial indicator trend analysis is way more than just evaluating Corcept Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Corcept Therapeutics is a good investment. Please check the relationship between Corcept Therapeutics Non Current Assets Total and its Total Current Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Non Current Assets Total vs Total Current Assets

Non Current Assets Total vs Total Current Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Corcept Therapeutics Non Current Assets Total account and Total Current Assets. At this time, the significance of the direction appears to have strong relationship.

The correlation between Corcept Therapeutics' Non Current Assets Total and Total Current Assets is 0.77. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Corcept Therapeutics Incorporated, assuming nothing else is changed. The correlation between historical values of Corcept Therapeutics' Non Current Assets Total and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of Corcept Therapeutics Incorporated are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Non Current Assets Total i.e., Corcept Therapeutics' Non Current Assets Total and Total Current Assets go up and down completely randomly.

Correlation Coefficient

0.77

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Most indicators from Corcept Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Corcept Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Selling General Administrative is likely to gain to about 193.1 M in 2024. Tax Provision is likely to gain to about 19.3 M in 2024

	2021	2022	2023	2024 (projected)
Other Operating Expenses	241.5M	289.2M	375.1M	393.8M
Research Development	113.9M	131.0M	184.4M	193.6M

Other Operating Expenses Research Development

Corcept Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Accounts Payable	Cash	Other Current Assets	Total Liab	Common Stock	Property Plant Equipment	Total Stockholder Equity	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Short Term Investments	Short Long Term Debt Total	Property Plant And Equipment Net	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total	Property Plant And Equipment Gross	Total Current Assets	Current Deferred Revenue
Total Assets		0.32	0.75	0.93	0.74	0.86	0.82	0.5	0.98	1.0	0.85	0.4	-0.16	0.93	-0.57	0.51	-0.76	0.9	0.86	0.96	0.97	0.52	0.03	0.46	0.99	0.91
Other Current Liab	0.32		0.34	0.24	0.5	0.16	0.15	0.34	0.27	0.34	0.44	0.3	0.14	0.49	-0.18	0.36	-0.5	0.22	0.23	0.36	0.34	0.28	-0.41	0.25	0.33	0.38
Total Current Liabilities	0.75	0.34		0.87	0.19	0.92	0.91	0.32	0.81	0.7	0.75	0.17	-0.36	0.6	-0.31	0.11	-0.22	0.75	0.91	0.69	0.6	0.36	-0.37	0.0	0.66	0.65
Accounts Payable	0.93	0.24	0.87		0.48	0.93	0.89	0.43	0.94	0.91	0.89	0.33	-0.23	0.79	-0.57	0.3	-0.51	0.87	0.97	0.83	0.83	0.47	-0.08	0.24	0.87	0.87
Cash	0.74	0.5	0.19	0.48		0.33	0.31	0.55	0.64	0.78	0.52	0.53	0.23	0.87	-0.4	0.74	-1.0	0.54	0.31	0.77	0.86	0.52	0.23	0.73	0.82	0.69
Other Current Assets	0.86	0.16	0.92	0.93	0.33		0.95	0.31	0.91	0.82	0.78	0.16	-0.47	0.68	-0.49	0.11	-0.36	0.91	0.94	0.83	0.75	0.36	-0.1	0.03	0.8	0.74
Total Liab	0.82	0.15	0.91	0.89	0.31	0.95		0.43	0.88	0.76	0.68	0.27	-0.32	0.64	-0.35	0.13	-0.34	0.8	0.88	0.83	0.72	0.48	0.0	0.05	0.76	0.65
Common Stock	0.5	0.34	0.32	0.43	0.55	0.31	0.43		0.44	0.48	0.33	0.97	0.54	0.47	0.12	0.36	-0.53	0.18	0.33	0.56	0.51	0.99	0.16	0.33	0.51	0.5
Property Plant Equipment	0.98	0.27	0.81	0.94	0.64	0.91	0.88	0.44		0.97	0.83	0.31	-0.24	0.9	-0.53	0.44	-0.67	0.92	0.88	0.94	0.94	0.47	0.01	0.39	0.96	0.86
Total Stockholder Equity	1.0	0.34	0.7	0.91	0.78	0.82	0.76	0.48	0.97		0.86	0.39	-0.15	0.95	-0.59	0.56	-0.8	0.9	0.82	0.94	0.98	0.5	0.02	0.51	0.99	0.93
Other Assets	0.85	0.44	0.75	0.89	0.52	0.78	0.68	0.33	0.83	0.86		0.29	-0.18	0.77	-0.6	0.39	-0.55	0.79	0.91	0.74	0.76	0.36	-0.35	0.3	0.79	0.95
Common Stock Shares Outstanding	0.4	0.3	0.17	0.33	0.53	0.16	0.27	0.97	0.31	0.39	0.29		0.69	0.39	0.19	0.4	-0.5	0.03	0.24	0.44	0.42	0.94	0.13	0.37	0.41	0.48
Other Stockholder Equity	-0.16	0.14	-0.36	-0.23	0.23	-0.47	-0.32	0.54	-0.24	-0.15	-0.18	0.69		-0.01	0.5	0.42	-0.19	-0.57	-0.32	-0.17	-0.08	0.49	0.06	0.46	-0.12	-0.04
Short Term Investments	0.93	0.49	0.6	0.79	0.87	0.68	0.64	0.47	0.9	0.95	0.77	0.39	-0.01		-0.51	0.69	-0.89	0.79	0.68	0.9	0.97	0.47	0.01	0.65	0.96	0.84
Short Long Term Debt Total	-0.57	-0.18	-0.31	-0.57	-0.4	-0.49	-0.35	0.12	-0.53	-0.59	-0.6	0.19	0.5	-0.51		-0.21	0.45	-0.71	-0.52	-0.49	-0.55	0.09	-0.16	-0.17	-0.55	-0.56
Property Plant And Equipment Net	0.51	0.36	0.11	0.3	0.74	0.11	0.13	0.36	0.44	0.56	0.39	0.4	0.42	0.69	-0.21		-0.73	0.26	0.2	0.47	0.61	0.33	-0.03	0.98	0.58	0.52
Net Debt	-0.76	-0.5	-0.22	-0.51	-1.0	-0.36	-0.34	-0.53	-0.67	-0.8	-0.55	-0.5	-0.19	-0.89	0.45	-0.73		-0.58	-0.35	-0.79	-0.88	-0.49	-0.22	-0.72	-0.84	-0.71
Retained Earnings	0.9	0.22	0.75	0.87	0.54	0.91	0.8	0.18	0.92	0.9	0.79	0.03	-0.57	0.79	-0.71	0.26	-0.58		0.83	0.87	0.85	0.22	0.01	0.2	0.88	0.79
Non Current Assets Total	0.86	0.23	0.91	0.97	0.31	0.94	0.88	0.33	0.88	0.82	0.91	0.24	-0.32	0.68	-0.52	0.2	-0.35	0.83		0.75	0.72	0.39	-0.26	0.12	0.77	0.85
Non Currrent Assets Other	0.96	0.36	0.69	0.83	0.77	0.83	0.83	0.56	0.94	0.94	0.74	0.44	-0.17	0.9	-0.49	0.47	-0.79	0.87	0.75		0.96	0.57	0.15	0.41	0.96	0.83
Cash And Short Term Investments	0.97	0.34	0.6	0.83	0.86	0.75	0.72	0.51	0.94	0.98	0.76	0.42	-0.08	0.97	-0.55	0.61	-0.88	0.85	0.72	0.96		0.52	0.14	0.58	1.0	0.86
Common Stock Total Equity	0.52	0.28	0.36	0.47	0.52	0.36	0.48	0.99	0.47	0.5	0.36	0.94	0.49	0.47	0.09	0.33	-0.49	0.22	0.39	0.57	0.52		0.15	0.31	0.53	0.52
Non Current Liabilities Total	0.03	-0.41	-0.37	-0.08	0.23	-0.1	0.0	0.16	0.01	0.02	-0.35	0.13	0.06	0.01	-0.16	-0.03	-0.22	0.01	-0.26	0.15	0.14	0.15		0.06	0.1	-0.16
Property Plant And Equipment Gross	0.46	0.25	0.0	0.24	0.73	0.03	0.05	0.33	0.39	0.51	0.3	0.37	0.46	0.65	-0.17	0.98	-0.72	0.2	0.12	0.41	0.58	0.31	0.06		0.53	0.45
Total Current Assets	0.99	0.33	0.66	0.87	0.82	0.8	0.76	0.51	0.96	0.99	0.79	0.41	-0.12	0.96	-0.55	0.58	-0.84	0.88	0.77	0.96	1.0	0.53	0.1	0.53		0.89
Current Deferred Revenue	0.91	0.38	0.65	0.87	0.69	0.74	0.65	0.5	0.86	0.93	0.95	0.48	-0.04	0.84	-0.56	0.52	-0.71	0.79	0.85	0.83	0.86	0.52	-0.16	0.45	0.89

Click cells to compare fundamentals

Corcept Therapeutics Account Relationship Matchups

Corcept Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	412.3M	571.7M	423.8M	583.4M	621.5M	652.6M
Other Current Liab	30.1M	(2.1M)	(526K)	68.5M	654K	621.3K
Total Current Liabilities	41.1M	10.6M	6.9M	81.6M	104.5M	109.7M
Accounts Payable	7.5M	10.6M	6.9M	12.0M	17.4M	18.3M
Cash	315.3M	476.9M	335.8M	436.6M	135.6M	116.6M
Other Current Assets	6.0M	6.7M	10.3M	16.4M	27.6M	28.9M
Total Liab	41.1M	48.4M	48.0M	81.6M	114.8M	120.6M
Common Stock	120K	122K	127K	131K	133K	85.9K
Property Plant Equipment	1.1M	1.7M	1.0M	1.8M	2.0M	2.1M
Total Stockholder Equity	371.2M	523.3M	375.8M	501.8M	506.7M	532.0M
Other Assets	61.1M	52.9M	43.5M	77.5M	89.1M	93.5M
Common Stock Shares Outstanding	122.6M	124.2M	126.0M	116.0M	111.7M	83.1M
Liabilities And Stockholders Equity	412.3M	571.7M	423.8M	583.4M	621.5M	652.6M
Other Stockholder Equity	394.4M	440.3M	180.9M	206.2M	103.4M	98.3M
Short Term Investments	244.7M	364.5M	145.9M	365.3M	232.7M	244.3M
Property Plant And Equipment Net	3.4M	2.5M	514K	1.1M	315K	559.2K
Net Debt	(311.9M)	(474.3M)	(335.3M)	(435.5M)	(135.4M)	(142.2M)
Retained Earnings	(23.6M)	82.5M	195.0M	296.4M	402.5M	422.7M
Non Current Assets Total	59.7M	47.5M	42.4M	84.7M	162.9M	171.0M
Non Currrent Assets Other	10.5M	13.4M	14.4M	17.2M	14.8M	15.5M
Cash And Short Term Investments	315.3M	476.9M	335.8M	436.6M	368.2M	386.6M
Common Stock Total Equity	117K	120K	122K	127K	146.1K	87.7K
Non Current Liabilities Total	1.9M	37.8M	41.0M	9.1M	10.3M	12.7M
Property Plant And Equipment Gross	4.5M	4.2M	514K	1.1M	315K	299.3K
Total Current Assets	352.6M	524.2M	381.4M	498.7M	458.6M	481.6M
Accumulated Other Comprehensive Income	261K	415K	(227K)	(869K)	609K	639.5K
Net Tangible Assets	371.2M	523.3M	375.8M	501.8M	577.1M	606.0M
Retained Earnings Total Equity	(117.7M)	(23.6M)	82.5M	195.0M	224.2M	235.4M
Capital Surpluse	417.2M	457.1M	516.1M	591.3M	680.1M	426.4M
Inventory	17.4M	21.2M	18.0M	17.0M	7.7M	9.6M
Net Receivables	19.9M	26.2M	27.6M	45.1M	55.1M	57.9M
Net Invested Capital	371.2M	523.3M	375.8M	501.8M	506.7M	431.5M
Long Term Investments	39.4M	36.2M	112.3M	4.9M	57.2M	41.7M

Corcept Therapeutics Investors Sentiment

The influence of Corcept Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Corcept. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to Corcept Therapeutics' public news can be used to forecast risks associated with an investment in Corcept. The trend in average sentiment can be used to explain how an investor holding Corcept can time the market purely based on public headlines and social activities around Corcept Therapeutics Incorporated. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Corcept Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Corcept Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Corcept Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Corcept Therapeutics.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Corcept Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Corcept Therapeutics' short interest history, or implied volatility extrapolated from Corcept Therapeutics options trading.

Pair Trading with Corcept Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corcept Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corcept Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Corcept Stock

0.66

AEZS

Aeterna Zentaris Financial Report 14th of May 2024

Pair Corr

Moving against Corcept Stock

0.65	ZJYL	JIN MEDICAL INTERNATIONAL	Pair Corr
0.62	PDEX	Pro Dex Earnings Call Today	Pair Corr

The ability to find closely correlated positions to Corcept Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corcept Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corcept Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corcept Therapeutics Incorporated to buy it.

The correlation of Corcept Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corcept Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corcept Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Corcept Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Corcept Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Corcept Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Corcept Therapeutics Incorporated Stock. Highlighted below are key reports to facilitate an investment decision about Corcept Therapeutics Incorporated Stock:

How To Invest In Corcept

Details

Is Corcept Stock a good investment?

Details

What is Corcept Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Corcept Stock analysis

When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities

Is Corcept Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corcept Therapeutics. If investors know Corcept will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corcept Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.995

Earnings Share

0.94

Revenue Per Share

4.658

Quarterly Revenue Growth

0.314

Return On Assets

0.1113

The market value of Corcept Therapeutics is measured differently than its book value, which is the value of Corcept that is recorded on the company's balance sheet. Investors also form their own opinion of Corcept Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Corcept Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corcept Therapeutics' market value can be influenced by many factors that don't directly affect Corcept Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Corcept Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corcept Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corcept Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Corcept Non Current Assets Total vs Total Current Assets Analysis

Non Current Assets Total vs Total Current Assets

Non Current Assets Total vs Total Current Assets Correlation Analysis

Correlation Coefficient

Non Current Assets Total

Total Current Assets

Corcept Therapeutics fundamental ratios Correlations

Corcept Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Corcept Therapeutics fundamental ratios Accounts

Corcept Therapeutics Investors Sentiment

Pair Trading with Corcept Therapeutics

Moving together with Corcept Stock

Moving against Corcept Stock

Complementary Tools for Corcept Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Current Assets	+ 0.99	Total Assets
Common Stock Total Equity	+ 0.99	Common Stock
Total Current Assets	+ 0.99	Total Stockholder Equity
Property Plant Equipment	+ 0.98	Total Assets

Net Debt	- 1.0	Cash
Net Debt	- 0.89	Short Term Investments
Cash And Short Term Investments	- 0.88	Net Debt
Total Current Assets	- 0.84	Net Debt
Net Debt	- 0.8	Total Stockholder Equity
Non Currrent Assets Other	- 0.79	Net Debt